Don't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag

Regencell Bioscience is working on TCM opportunities, but what exactly is TCM?

Precision BioSciences stock jumps on FDA Fast Track status

Precision BioSciences (NASDAQ:DTIL) shares rose 13% Monday following the FDA’s Fast Track designation for PBGENE-DMD, its gene editing therapy for Duchenne muscular dystrophy. The Fast Track ...

Mid-cap NovaBridge Biosciences stock jumps fueled by positive study data in eye disease

NovaBridge Biosciences NBP shares are up on Monday following the announcement of positive topline results from the Phase 2a study of VIS-101, a treatment for retinal vascular diseases. Trial Data The ...

Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now

I wouldn't touch Regencell with a 10-foot pole because of the high risks involved in the business. That includes the lack of a product, the focus on TCM, and the very nature of the early stage ...

Solid Biosciences stock jumps on $240M private placement

Solid Biosciences Inc. (NASDAQ:SLDB) shares rose 14% after the company announced an oversubscribed $240 million private placement with institutional investors. Th ...

Arcus Biosciences: Q4 Beat And Casdatifan's Story So Far

Arcus Biosciences beat FY25 EPS/revenue estimates as Casdatifan drives upside; $1.01B cash funds Phase 3 into 2H28. Click for ...

Harvard Bioscience, Inc.: Harvard Bioscience Announces Reverse Stock Split

Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: ...

Hyundai Bioscience joins dengue fever clinical trial in Vietnam

South Korea's Hyundai Bioscience said Friday it has joined a global clinical trial in Vietnam for dengue fever, a mosquito-borne viral disease.

Niagen Bioscience targets 10–15% revenue growth for 2026 while expanding injectable product line

Q4 2025 earnings call: revenue, margins, 2026 growth guidance, Niagen Plus injection kits, telehealth plans & FDA lawsuit—read now.
Las Vegas Sun

Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules

Forte Biosciences, Inc. ( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with ...
The Manila Times

Solid Biosciences Announces Oversubscribed $240 Million Private Placement

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities ...

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipa ...